CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.44+0.29 (+6.99%)
Close on Nov 18, 2026Market cap $6.49MP/E –Yield –
CNS Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CNS Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$16.91M. For fiscal 2025 it was -$15.99M. The highest annual figure on record is -$881.79K in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.99M | – |
| FY2024 | Dec 31, 2024 | -$14.90M | – |
| FY2023 | Dec 31, 2023 | -$18.87M | – |
| FY2022 | Dec 31, 2022 | -$15.27M | – |
| FY2021 | Dec 31, 2021 | -$14.49M | – |
| FY2020 | Dec 31, 2020 | -$9.45M | – |
| FY2019 | Dec 31, 2019 | -$3.83M | – |
| FY2018 | Dec 31, 2018 | -$881.79K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.61M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$699.09K | – |
| Q2 FY2019 | Jun 30, 2019 | -$415.06K | – |
| Q1 FY2019 | Mar 31, 2019 | -$195.09K | – |
| Q4 FY2018 | Dec 31, 2018 | -$208.58K | – |
| Q3 FY2018 | Sep 30, 2018 | -$169.91K | – |
See a number that looks wrong?